TTY Biopharm is the leading pharmaceutical company specialized on oncology in Taiwan. With recent optimistic new about securing health authority sales approval for oral drug TS1 for gastric cancer patients in Taiwan, this newly partnership with US company is polishing and sharpen the future development in Taiwan and China.
BioDelivery Sciences Announces Commercial Partnership for BEMA Fentanyl in Taiwan -BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced a license and supply agreement with TTY Biopharm Co., Ltd., for the exclusive rights to develop and commercialize BEMA Fentanyl (marketed as ONSOLIS in the U.S.) in the Republic of China, Taiwan. The agreement results in potential milestone payments to BDSI of up to $1,300,000, which includes an upfront payment of $300,000. In addition, BDSI will receive an ongoing royalty based on net sales. “We are very pleased to have TTY as our commercialization partner for Taiwan to introduce BEMA Fentanyl into this rapidly growing market,” said Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI. “TTY has a strong market presence in Taiwan and a significant product portfolio in oncology, making BEMA Fentanyl an excellent fit for their organization.” TTY will be responsible for the regulatory filing of BEMA Fentanyl in Taiwan as well as future commercialization in that territory. BEMA Fentanyl is approved in the U.S. and Canada, under the trade name ONSOLIS, for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer. BEMA Fentanyl is licensed to Meda for all territories with the exception of Taiwan and South Korea. In South Korea, BEMA Fentanyl is licensed to Kunwha Pharmaceutical Co.
No comments:
Post a Comment